Australia Needs Stronger Leadership For Biotech To Prosper
As Australia ends a resources boom, a decline in manufacturing has left the country vulnerable, and a concerted investment in biotechnology could transform the country, according to a new report.
You may also be interested in...
Executing on its planned strategy for an 'exit' exactly on schedule, Australian/US biotech Spinifex Pharmaceuticals has agreed to be acquired by Novartis for $200m plus undisclosed development and regulatory milestones.
In final rule describing the types of evidence the agency will consider in determining the ‘intended use’ of a product, FDA rejects industry requests to exclude ‘circumstances surrounding distribution’ and product design or composition.
User fees for FY 2021 were set to increase nearly 11%, but could have gone even higher; a new notice will be issued but timing is unclear.